Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Akebia Therapeutics

Request full access

Development and commercialization of therapeutics for patients with chronic kidney disease

Cambridge, United StatesFounded 2007Biotech & Life Sciences

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with chronic kidney disease (CKD). The company primarily focuses on addressing anemia associated with CKD through its lead product candidate, vadadustat, which is currently undergoing global Phase 3 clinical trials. Akebia serves patients, families, and medical professionals by providing cutting-edge treatments aimed at improving the quality of life for those affected by kidney disease. Operating in the biopharmaceutical market, Akebia's business model involves extensive research and development, clinical trials, and strategic partnerships to bring its therapies to market. Revenue is generated through product sales, licensing agreements, and collaborations with other healthcare organizations. The company is headquartered in Cambridge, MA, and actively participates in major healthcare conferences to present its findings and advancements.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2014
Outcome tier
Thoroughbred$100M+ revenue

Akebia Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Akebia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • CincyTech

Series A8 investors entered at this stage

  • Venture Investors Health Fund
  • Novartis Venture Fund
  • Athenian Venture Partners
  • Kearny Venture Partners
  • Orchard Venture Partners
  • Triathlon Medical Venture Partners
  • QCA Ventures
  • GeneChem

Series B and later3 investors entered at this stage

  • Novo Seeds
  • Novo Holdings
  • Kreos Capital
Employees mapped 270 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 27 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
7 countries with
team presence
🇺🇸 United States97%
🇩🇪 Germany0.5%
🇬🇭 Ghana0.5%
🇨🇳 China0.5%
🇪🇸 Spain0.5%
Top 5 of 7 shown
Web traffic by country
8.7K monthly visits
across markets
🇺🇸 United States81.6%
🇨🇦 Canada12.6%
🇧🇪 Belgium5.7%
Top 3 markets shown

Patents

Estimated portfolio value
$80M

50 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Akebia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Akebia Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.